key: cord-0770966-7i81cm5y authors: Klein, David E.; Libman, Richard; Kirsch, Claudia; Arora, Rohan title: Cerebral Venous Thrombosis: Atypical Presentation of COVID-19 in the Young date: 2020-05-23 journal: J Stroke Cerebrovasc Dis DOI: 10.1016/j.jstrokecerebrovasdis.2020.104989 sha: 6097bf37ebedd8b582e03dec6778343952335d3b doc_id: 770966 cord_uid: 7i81cm5y Abstract Objective Identify clinical and radiographic features of venous infarct as a presenting feature of COVID-19 in the young. Background SARS-CoV-2 infection causes hypercoagulability and inflammation leading to venous thrombotic events (VTE). Although elderly patients with comorbidities are at higher risk, COVID-19 may also cause VTE in a broader patient population without these risks. Neurologic complications and manifestations of COVID-19, including neuropathies, seizures, strokes and encephalopathy usually occur in severe established cases of COVID-19 infection who primarily present with respiratory distress. Case description : Case report of a 29-year-old woman, with no significant past medical history or comorbidities, presenting with new onset seizures. Further questioning revealed a one-week history of headaches, low-grade fever, mild cough and shortness of breath, diagnosed as COVID-19. Imaging revealed a left temporoparietal hemorrhagic venous infarction with left transverse and sigmoid sinus thrombosis treated with full dose anticoagulation and antiepileptics. Conclusion Although elderly patients with comorbidities are considered highest risk for COVID-19 neurologic complications, usually when systemic symptoms are severe, this case report emphasizes that young individuals are at risk for VTE with neurologic complications even when systemic symptoms are mild, likely induced by COVID-19 associated hypercoagulable state. and sigmoid sinus thrombosis treated with full dose anticoagulation and antiepileptics. Emerging data suggest a novel highly virulent strain of a β-coronaviruses (CoV), coronavirus infectious disease (COVID-19), may confer a particularly high risk of stroke 4-6 . Severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1), Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV) and now severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been linked to para-infectious stroke 3-6 . Hypercoagulability of SARS-CoV2, manifesting as increase in D-dimer, lactate dehydrogenase (LDH) and prolonged coagulation times is associated with more severe disease and can help risk stratify patients on presentation 7 . However, the resultant venous thrombotic events (VTEs) including deep vein thrombosis (DVT) and pulmonary embolism (PE), are more often reported to occur later in COVID-19's disease course [8] [9] [10] . In addition to fever, dry cough, shortness of breath and myalgias, neurologic signs and symptoms may occur due to COVID-19. Neurologic sequelae such as anosmia, ageusia, headache, dizziness and altered sensorium may occur due to direct viral infection or as secondary complications of SARS-CoV2 11-13 . This case report presents a 29-year-old woman with a Dural Venous Sinus Thrombosis (DVST) early in the course of COVID-19. A 29-year-old right-handed woman with no known medical history presented with new onset generalized tonic-clonic seizures with post-ictal confusion. She later reported that prior to admission, she had over a week of cough, low grade fever, mild shortness of breath and a mild headache. She took no regular medications, including no hormonal contraceptives. On initial exam, she was afebrile, mildly agitated, and complaining of neck pain. She was breathing room air with an oxygen saturation of 100% and had a body mass index of 17.4. While in the emergency department she had a third seizure, was given Lorazepam 2mg IV, loaded with Levetiracetam 1,000 mg IV and started on Levetiracetam 750 mg IV twice daily. Initial neurologic exam was notable for decreased level of arousal, global aphasia, decreased blink to threat on the right and a mild to moderate right facial palsy. There was spontaneous movement against gravity in all four limbs with slightly less movement of the right upper extremity. Initial non-contrast head CT demonstrated left temporoparietal hemorrhagic venous infarct with edema and mass effect with 5mm rightward shift as well as venous thrombosis in distal left transverse and sigmoid sinus (Figure 1 ). Nasal swab polymerase chain reaction (PCR) was positive for COVID-19. She had a notable microcytic anemia with hemoglobin of 5.5 g/dL on admission, determined to be due to iron deficiency secondary to menorrhagia, treated with two units of packed red blood cells and started on ferrous sulfate 325 mg daily. Additional laboratory findings, consistent with COVID-19 included elevated LDH, CRP, and D-dimer levels. Laboratory values, including a normal coagulation profile, are included (Table 1) Additionally demonstrated flow related signal in the right transvers and sigmoid sinus extending to a patent right internal jugular vein (Figure 3 ). The day after admission, she continued to have a waxing and waning level of arousal and complained of diplopia. On exam, there were bilateral 6th nerve palsies and fundoscopy demonstrated bilateral papilledema. She was started on acetazolamide 500 mg twice daily with accompanying serial fundoscopic exams. Over the next seven days, she improved clinically in alertness and had a moderate mixed aphasia with persistent bilateral 6th nerve palsies. Hypercoagulability induced by COVID-19 has been implicated in PEs, VTEs, disseminated intravascular coagulation (DIC) and recently in stroke 9, 14, 15 . Postulated mechanisms of hypercoagulability include disruptions in the renin-angiotensin (RAS) system with reduction in ACE2 and Ang-1-7 and alterations in the coagulation cascade leading to a consumptive coagulopathy and cytokine storm including IL-1, IL-6 & TNF-α. This is a significant consideration while evaluating stroke patients in the setting of COVID-19. In this patient's case with no past medical history, she had potential competing mechanisms of hypercoagulability, including iron deficiency anemia, a possible β or δ thalassemia trait and increased anticardiolipin IgM serum titers. Anticardiolipin antibodies have been shown to rise in acute hypercoagulable states, certain cases of systemic viral infections and even in acute stroke 14 . Thus, the anticardiolipin antibody increase in our patient's case may or may not have contributed to her DSVT, and this cannot be determined without future re-testing. This suggests advanced COVID-19 provoked hypercoagulability likely contributed to her DVST. The neurologic manifestations of COVID-19, including stroke, are usually reported later in the disease course [4] [5] [6] 10, 11 . Though both cerebral venous infarction and COVID-19 can occur in the young, cerebral venous thrombosis and infarction is a rare documented early presentation of COVID 19. The patient did have fever, shortness of breath and a cough, minor in severity, which were not presenting complaints on admission. Regarding treatment, the choice of anticoagulants in COVID-19 associated VTEs is a matter of debate 19 . Both unfractionated heparin and low molecular weight heparins are used in acute DVST. Emerging evidence suggests that various heparins can bind to the COVID-19 spike proteins, help downregulate IL-6, and directly dampen immune activation 20 . Theoretically this may be of clinical benefit. Alternative treatments that interact with the ACE2 receptors are also being postulated, although clinical trials have not yet occurred. 21, 22 Conclusion: Hypercoagulability is a known complication of COVID-19. Although severe cases are usually reported in older populations and in those with underlying comorbidities, this case report emphasizes that this may occur in young individuals without significant medical history. Light blue arrows denoting normal flow related signal in the right transvers and sigmoid sinus extending to a patent right internal jugular vein. Cerebral venous thrombosis Cerebral Venous Thrombosis Large artery ischaemic stroke in severe acute respiratory syndrome (SARS) The Spectrum of Neurologic Disease in the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic Infection Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: A Retrospective Case Series Study CORONAVIRUSES INDUCED DISEASE: SYSTEMATIC REVIEW OF SARS-CoV, MERS-CoV, AND SARS-CoV D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis COVID-19 Complicated by Acute Pulmonary Embolism Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 Clinical Characteristics of Coronavirus Disease 2019 in China Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy. Cureus The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients Acute Necrotizing Encephalopathy in an Adult Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 Infected Patients Exhibit Increased Clot Waveform Analysis Parameters Consistent with Hypercoagulability Acute stroke management pathway during Coronavirus-19 pandemic Protected Code Stroke Murine Coronavirus with an Extended Host Range Uses Heparan Sulfate as an Entry Receptor Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis Analysis of thrombotic factors in severe acute respiratory syndrome (SARS) patients A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury Mas Axis in Brain: A Potential Target for Prevention and Treatment of Ischemic Stroke